Objective: Opioids are increasingly prescribed in the West and have deleterious GI consequences. Pharmacological therapies to treat opioid-induced constipation (OIC) are available, but their relative efficacy is unclear. We performed a systematic review and network meta-analysis to address this deficit in current knowledge.
Design: We searched MEDLINE, EMBASE, EMBASE Classic and the Cochrane central register of controlled trials through to December 2017 to identify randomised controlled trials (RCTs) of pharmacological therapies in the treatment of adults with OIC. Trials had to report a dichotomous assessment of overall response to therapy, and data were pooled using a random effects model. Efficacy and safety of pharmacological therapies was reported as a pooled relative risk (RR) with 95% CIs to summarise the effect of each comparison tested and ranked treatments according to their P-score.
Results: Twenty-seven eligible RCTs of pharmacological therapies, containing 9149 patients, were identified. In our primary analysis, using failure to achieve an average of ≥3 bowel movements (BMs) per week with an increase of ≥1 BM per week over baseline or an average of ≥3 BMs per week, to define non-response, the network meta-analysis ranked naloxone first in terms of efficacy (RR=0.65; 95% CI 0.52 to 0.80, P-score=0.84), and it was also the safest drug. When non-response to therapy was defined using failure to achieve an average of ≥3 BMs per week, with an increase of ≥1 BM per week over baseline, naldemedinewas ranked first (RR=0.66; 95% CI 0.56 to 0.77, P score=0.91) and alvimopan second (RR=0.74; 95% CI 0.57 to 0.94, P-score=0.71).
Conclusion: In network meta-analysis, naloxone and naldemedine appear to be the most efficacious treatments for OIC. Naloxone was the safest of these agents.
Keywords: constipation; meta-analysis.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: PL, NEB and ACF: none declared. DMB has acted as a consultant, advisor and speaker for Synergy, Allergan, Ironwood, AstraZeneca, Daiichi Sankyo, Shionogi, Salix Pharmaceuticals, Medscape LLC, Medtronic and GI Health Foundation.
Efficacy of Drugs in Chronic Idiopathic Constipation: A Systematic Review and Network Meta-AnalysisP Luthra et al. Lancet Gastroenterol Hepatol 4 (11), 831-844. PMID 31474542.Almost all drugs studied were superior to placebo, according to either failure to achieve three or more CSBMs per week or or failure to achieve an increase of one or more …
Efficacy of Pharmacological Therapies for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-AnalysisAC Ford et al. Am J Gastroenterol 108 (10), 1566-74; quiz 1575. PMID 23752879. - Reviewμ-Opioid receptor antagonists are safe and effective for the treatment of OIC. More data are required before the role of prucalopride or lubiprostone in the treatment of …
Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysisJ Nee et al. Clin Gastroenterol Hepatol 16 (10), 1569-1584.e2. PMID 29374616. - Meta-AnalysisIn a systematic review and meta-analysis, we found μ-opioid-receptor antagonists to be safe and effective for the treatment of OIC. Prescription-strength laxatives (pruca …
Efficacy of Soluble Fibre, Antispasmodic Drugs, and Gut-Brain Neuromodulators in Irritable Bowel Syndrome: A Systematic Review and Network Meta-AnalysisCJ Black et al. Lancet Gastroenterol Hepatol 5 (2), 117-131. PMID 31859183.In this network meta-analysis of RCTs of soluble fibre, antispasmodic drugs, peppermint oil, and gut-brain neuromodulators for IBS, few of which were judged as being at a …
Mu-opioid Antagonists for Opioid-Induced Bowel Dysfunction in People With Cancer and People Receiving Palliative CareB Candy et al. Cochrane Database Syst Rev 6 (6), CD006332. PMID 29869799. - ReviewIn this update, the conclusions for naldemedine are new. There is moderate-quality evidence to suggest that, taken orally, naldemedine improves bowel function over two we …
Cited by 5 PubMed Central articles
Safety and Efficacy of Naldemedine in Cancer Patients With Opioid-Induced Constipation: A Pooled, Subgroup Analysis of Two Randomised Controlled StudiesI Osaka et al. ESMO Open 4 (4), e000527. PMID 31423335.Although not powered to detect statistically significant differences in treatment effect among subgroups, this study demonstrated that naldemedine appeared to benefit pat …
Naldemedine: A Review in Opioid-Induced ConstipationHA Blair. Drugs 79 (11), 1241-1247. PMID 31267482. - ReviewNaldemedine [Symproic® (Japan; USA); Rizmoic® (EU)], an orally available peripherally acting μ-opioid receptor antagonist (PAMORA), is approved in s …
A Preliminary Study of the Effect of Naldemedine Tosylate on Opioid-Induced Nausea and VomitingJ Sato et al. Support Care Cancer 28 (3), 1083-1088. PMID 31183560.For patients with constipation, using NALD at an early stage of opioid initiation might have secondary benefits, such as relief from OINV, besides improvement of OIC. To …
Pharmacological and Non-Pharmacological Treatments for Opioid-Induced Constipation: A Protocol for Systematic Review and Network Meta-AnalysisJ Zhang et al. Medicine (Baltimore) 98 (4), e14161. PMID 30681581.This study will provide a comprehensive evidence on the effectiveness and safety of pharmacological and non-pharmacological treatments for opioid-induced constipation. …
American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced ConstipationB Hanson et al. Gastroenterology 156 (1), 229-253.e5. PMID 30337104. - Review